Post

Magazine: Lula’s progress plan for Brazil: a year on

Almost one year ago, Brazilian president Lula da Silva assembled the first South American summit in nearly a decade to …

Boehringer outlines up to $33.6m for cancer asset from OSE Therapeutics

Boehringer Ingelheim has bought a preclinical oncology asset from long-time collaborator OSE Immunotherapeutics, in addition to expanding the scope of …

Otsuka cuts development for AVP-786 following Phase III flop

Otsuka Pharmaceutical has axed the development of its dementia drug, AVP-786, following a disappointing Phase III readout (NCT03393520). The Japanese company …

Pfizer starts $1.5bn cost-cutting initiative amidst declining Covid-19 revenues

Pfizer has unveiled another cost reduction programme, which is expected to run over multiple years and will result in savings …

Overcoming the barriers to diverse and inclusive patient recruitment

In a bid to answer the long-standing question of diversity in clinical trials, experts came together to address the lingering …